Public Health Advisories

Public Health Advisories for 2008

• Suicidal Thoughts and Behavior Antiepileptic Drugs (12/16/2008)
• National Transition from Chlorofluorocarbon (CFC) Propelled Albuterol Inhalers to Hydrofluroalkane (HFA) Propelled Albuterol Inhalers (5/30/2008, updated 8/28/2008)
• Important Information for the Safe Use of Tussionex Pennkinetic Extended-Release Suspension (3/11/2008)
• Important Information on the Correct Use of Spiriva and Foradil Capsules (2/29/2008)
• Important Warnings and Instructions for Heparin Sodium Injection (Baxter) (2/11/2008)
• Important Information on Chantix (varenicline) (2/1/2008)
• FDA Recommends that Over-the-Counter (OTC) Cough and Cold Products not be used for Infants and Children under 2 Years of Age (1/17/2008, updated 10/10/2008)
• Edetate Disodium (marketed as Endrate and generic products) (1/16/2008)

Public Health Advisories for 2007

• Fentanyl Transdermal System (Patch) (marketed as Duragesic and generics) (12/21/2007)
• Erythropoiesis-Stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit and Epogen), Darbepoetin alfa (marketed as Aranesp) (11/8/2007)
• Fentanyl Buccal Tablets (marketed as Fentora) (9/26/2007)
• Use of Codeine By Some Breastfeeding Mothers May Lead To Life-Threatening Side Effects In Nursing Babies (8/17/2007)
• Nonprescription Cough and Cold Medicine Use in Children (8/15/2007)
• Colistimethate (marketed as Coly-Mycin M and generic products) (6/28/2007)
• Tegaserod maleate (marketed as Zelnorm) (3/30/2007)
• Pergolide (marketed as Permax) (3/29/2007)
• Interferon gamma-1b (marketed as Actimmune) (3/9/2007)
• Erythropoiesis-Stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp) (3/9/2007)
• Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures (2/6/2007)

Public Health Advisories for 2006

• Update on Magnetic Resonance Imaging (MRI) Contrast Agents Containing Gadolinium and Nephrogenic Fibrosing Dermopathy (12/22/2006)
• Life-threatening Brain Infection in Patients with Systemic Lupus Erythematosus After Rituxan (Rituximab) Treatment (12/18/2006)
• Methadone Use for Pain Control May Result in Death and Life-Threatening Changes in Breathing and Heart Beat (11/27/2006)
• Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp) (11/16/2006)
• Aprotinin Injection (marketed as Trasylol) (9/29/2006)
• Treatment Challenges of Depression in Pregnancy and the Possibility of Persistent Pulmonary Hypertension in Newborns (7/19/2006)
• Combined Use of 5-Hydroxytryptamine Receptor Agonists (Triptans), Selective Serotonin Reuptake Inhibitors (SSRIs) or Selective Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) May Result in Life-threatening Serotonin Syndrome. (7/19/2006)
• Consumers Should Not Use Triaminic Vapor Patch (6/20/2006)
• Gadolinium-containing Contrast Agents for Magnetic Resonance Imaging (MRI) (6/8/2006)
• Angiotensin-Converting Enzyme Inhibitor (ACE inhibitor) Drugs and Pregnancy (6/7/2006)
• Diastat AcuDial (3/30/2006)
• Sepsis and medical abortion with mifepristone (Mifeprex) (3/17/2006)
• Benzocaine Sprays marketed under different names, including Hurricaine, Topex, and Cetacaine (2/10/2006)
• Trasylol (aprotinin injection) (2/8/2006)
• Ketek (telithromycin) Tables (1/20/2006)
• FDA warns of consequences of drug name confusion in U.S. prescriptions filled abroad.  FDA News  Public Health Advisory (1/11/2006)

Public Health Advisories for 2005

• NeutroSpec (12/19/2005)
• Paxil (paroxetine) (12/8/2005)
• Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder) (Long Acting Beta Agonists) (11/18/2005)
• Strattera (9/29/2005)
• Mifexprex (mifepristone) (7/19/2005)
• Duragesic (Fentanyl Transdermal System) (7/15/2005)
• Palladone (hydromorphone hydrochloride, extended release capsules) (7/13/2005)
• Suicidality in Adults Being Treated with Antidepressant Medications (6/30/2005)
• Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances (4/11/2005)
• FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (4/7/2005)
• Crestor (3/2/2005)
• Elidel (pimecrolimus) Cream and Protopic (tacrolimus) Ointment (3/10/2005)
• Tysabri (2/28/2005)
• Gabitril (2/18/2005)
• Adderall (2/9/2005)
• Viramune (1/19/2005)

Public Health Advisories for 2004

• Crestor (rosuvastatin) (6/9/2004)
• Safety of Vioxx  (9/30/2004)
• Non-Steroidal Anti-Inflammatory Drug Products (NSAIDS) (12/23/2004)
• Worsening Depression and Suicidality in Patients Being Treated with Antidepressant Medications  (3/22/2004)
• Suicidality in Children and Adolescents Being Treated With Antidepressant Medications (10/15/2004)

Public Health Advisories for 2003

• Lindane (3/28/2003)
• Reports of Suicidality in Pediatric Patients Being Treated with Antidepressant Medications for Major Depressive Disorder (MDD) (10/27/2003)

Public Health Advisory for 2002

• Contamination of Multi-dose Bottles of Albuterol Sulfate Solution for Inhalation (0.5%) (4/19/2002)

Public Health Advisories for 2001

• Sporonox and Lamisil for the Treatment of Onychomycosis (5/9/2001)
• Update on the Use of Doxycycline for Anthrax Exposure (10/18/2001)
• Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities - FDA Public Health Advisory.  Optional Format: PDF (4/5/2001)
• Miconazole Vaginal Cream and Suppositories Safety Information (3/5/2001) 

Public Health Advisories for 2000

• Safe and Appropriate Use of Influenza Drugs (1/12/2000)
• Safety of Phenylpropanolamine (11/6/2000)
• Risk of Drug Interactions with St. John's Wort and Indinavir and other Drugs (2/10/2000)
• Phenylpropanolamine Advisory (11/6/2000)
• Safe and Appropriate Use of Influenza Drugs (1/12/2000)

Public Health Advisories Pre-2000

• Trovan  Health Advisory (6/9/1999)
• Reports Of Valvular Heart Disease In Patients Receiving Concomitant Fenfluramine And Phentermine (7/1997)
• Reports Of Diabetes And Hyperglycemia In Patients Receiving Protease Inhibitors For The Treatment Of Human Immunodeficiency Virus (HIV) (6/1997)
• Synthetic Generic Conjugated Estrogens (5/1997)

Back to Top     Back to Drug Information

Date created: November 18, 2005, updated December 30, 2008

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research